Literature DB >> 2044252

Well-being (quality of life) in connection with hypertensive treatment.

C Dahlöf1.   

Abstract

Quality of life is often considered to equate how the medical treatment is subjectively perceived by the patient, but ought to include the total impact of the disease/treatment on the patient's emotional, physical, and social well-being. Recently, a proposal for a generally applicable definition of quality of life in health care was put forward. This definition includes general well-being, health, and welfare (external factors), as three fundamental components, and the definition is based on both objective and subjective judgments. General well-being is exclusively and expression of the individual's subjective experience and is based on his or her own qualitative evaluation of well-being in relation to condition, treatments, and experiences. Health is according to the proposed definition, judged both objectively (signs) and subjectively (symptoms). Apart from health and well-being, there is also reason to include objectively registrable factors at the welfare level (external factors) such as the consumption of medicines, number of days in hospital, length of sick leave, need of in-home care, etc. This review is an attempt to elucidate the effects of antihypertensive pharmacotherapy on the patient's general well-being. The topic will be discussed from several points of views (e.g., aims of antihypertensive treatment, occurrence of symptoms in the population, compliance with prescribed treatment, symptom inventories, the concept of quality of life.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2044252     DOI: 10.1002/clc.4960140204

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  6 in total

1.  Novel stratified medicines approach to manage uncontrolled hypertension due to multiple drug intolerances.

Authors:  Catherine Schuster Bruce; Gurvinder Rull; Antoniou Sotiris; Melvin D Lobo
Journal:  BMJ Case Rep       Date:  2018-12-13

Review 2.  Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  A N Wadworth; D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 3.  Enalapril: a review of quality-of-life and pharmacoeconomic aspects of its use in heart failure and mild to moderate hypertension.

Authors:  M I Wilde; H M Bryson; K L Goa
Journal:  Pharmacoeconomics       Date:  1994-08       Impact factor: 4.981

4.  Cost-effectiveness of antihypertensive treatment: metoprolol versus thiazide diuretics.

Authors:  M Johannesson; J Wikstrand; B Jönsson; G Berglund; J Tuomilehto
Journal:  Pharmacoeconomics       Date:  1993-01       Impact factor: 4.981

5.  Multiple drug-intolerant hypertension: a case series utilising a novel-treatment algorithm.

Authors:  Manish Saxena; Sotiris Antoniou; Nadya Hamedi; Paul Robinson; Harjit Singh; Omar Mukhtar; Vikas Kapil; Melvin D Lobo
Journal:  Br J Gen Pract       Date:  2016-04       Impact factor: 5.386

6.  General well-being during treatment with different ACE-inhibitors: two double-blind placebo-controlled cross-over studies in healthy volunteers.

Authors:  C Dahlöf; E Dimenäs
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.